Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by JohnEnglishon Mar 18, 2015 11:10am

62 Views

Post# 23533651

RE:RE:RE:Worth every penny!!

If the stock goes up that's great. :) As I said before it would be great to see a small Canadian pharma team make it big and I hope they do.

I have no other accounts here currently, and I never have. This is the only account I have ever registered on this board. Have I visited here before? Absolutely; I've been reading the Stockhouse forums for years but I have never actively participated in the discussions until now.

Saying that I'm using some kind of "tactics" is really giving me far too much credit. I am employing no tactics of any kind as I have no agenda.

Bullboard Posts

TELUS adds 347K customers in Q3